Hepion pharmaceuticals announces restructuring plan to enhance shareholder value and management changes

Restructuring program purpose is to preserve capital and optimize clinical development program management plans to continue to evaluate its phase 2b ascend-nash clinical trial taking in account current market environment cash runway extended into q2 2025 edison, n.j., dec. 07, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that its board of directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.
HEPA Ratings Summary
HEPA Quant Ranking